Skip to main content
Top
Published in: European Journal of Nutrition 5/2021

01-08-2021 | Correction

Correction to: The dietary inflammatory index is associated with anti and pro‑inflammatory adipokines in Brazilian schoolchildren

Authors: Lara Gomes Suhett, H. H. M. Hermsdorff, Sarah Aparecida Vieira Ribeiro, Mariana De Santis Filgueiras, Nitin Shivappa, James R. Hébert, Juliana Farias de Novaes

Published in: European Journal of Nutrition | Issue 5/2021

Login to get access

Excerpt

The original version of this article unfortunately contained a mistake. The presentation of Table 4 was incorrect and the legend of Table 1 is wrong in the article because those variables are not adjustment, and the P-value is from linear regression models, and not from Cochran-Armitage test. The corrected Tables 1 and 4 are given in the following page.
Table 1
Distribution of Children’s Dietary Inflammatory Index (C-DII) according to sociodemographic and behavior characteristics in schoolchildren from Viçosa, Minas Gerais, Brazil, 2015
Characteristics
n
C-DII
P valueb
Mean ± SD
Mean difference (95% CI)
Sex
 Male
181
0.6 ± 0.9
Reference
0.47
 Female
197
0.5 ± 0.9
− 0.1 (− 0.3, 0.1)
 
Age (years)
 8
183
0.5 ± 0.9
Reference
0.58
 9
195
0.6 ± 0.9
0.1 (− 0.1, 0.2)
 
Ethnicity
 White
119
0.3 ± 0.9
Reference
0.001*
 Non-white
259
0.7 ± 0.9
0.3 (0.1, 0.5)
 
School
 Private
110
0.3 ± 1.0
Reference
 < 0.001*
 Public
268
0.7 ± 0.9
0.3 (0.1, 0.5)
 
Per capita income (US$)a
 < 96.9 (1st quartile)
93
0.7 ± 0.9
Reference
0.001*
 97.0 < 155.3 (2nd quartile)
94
0.7 ± 0.9
0.0 (− 0.3, 0.2)
 
 155.4 < 262.2 (3rd quartile)
97
0.6 ± 0.9
− 0.1 (− 0.3, 0.2)
 
 > 262.3 (4th quartile)
94
0.3 ± 1.0
− 0.4 (− 0.6, − 0.1)
 
Screen time (hours/day)
 ≤ 2
198
0.5 ± 0.9
Reference
0.22
 > 2 (sedentary behavior)
180
0.6 ± 1.0
0.1 (− 0.1, 0.3)
 
SD standard deviation, 95% CI 95% confidence interval
*P < 0.05
aApproximate exchange rates of real (R$) to dollar (US$) at the time of this study (US$1.00 = R$ 3.22)
bFrom linear regression models. For variables with three or more categories, P value was from Wald test for linear trend representing ordinal categories as continuous
Table 4
Crude and adjusted analyses of the association between Children’s Dietary Inflammatory Index (C-DII) and adipokines in schoolchildren from Viçosa, Minas Gerais, Brazil, 2015
Adipokines
C-DII (quintiles)
Per 1 SD
P trendd
Q1 (− 2.16 to − 0.19) (n = 75)
Q2 (− 0.20 to 0.41) (n = 76)
Q3 (0.42–0.86) (n = 76)
Q4 (0.87–1.41) (n = 76)
Q5 (1.42–2.75) (n = 75)
 
Adiponectin (μg/mL)
 Mean ± SD
14.5 ± 7.7
14.6 ± 7.8
12.4 ± 6.3
13.6 ± 7.5
12.6 ± 7.5
   
 Unadjusted difference (95% CI)a
Reference
0.2 (− 2.3, 2.6)
− 2.0 (− 4.3, 0.2)
− 0.8 (− 3.3, 1.6)
− 1.8 (− 4.3, 0.6)
− 0.7 (− 1.5, − 0.04)
0.04*
 Adjusted difference (95% CI)b
Reference
0.1 (− 2.4, 2.6)
− 2.2 (− 4.5, 0.1)
− 1.0 (− 3.5, 1.5)
− 1.9 (− 4.4, 0.6)
− 0.8 (− 1.6, − 0.1)
0.04*
 Adjusted difference (95% CI)c
Reference
0.2 (− 2.2, 2.7)
− 2.0 (− 4.3, 0.2)
− 0.8 (− 3.2, 1.7)
− 1.9 (− 4.4, 0.6)
− 0.8 (− 1.5, − 0.03)
0.04*
Leptin (ng/mL)
 Mean ± SD
6.0 ± 11.3
5.7 ± 8.9
5.0 ± 7.7
6.8 ± 10.6
5.0 ± 8.5
   
 Unadjusted difference (95% CI)a
Reference
− 0.3 (− 3.6, 2.9)
− 1.0 (− 4.1, 2.0)
0.8 (− 2.7, 4.3)
1.0 (4.2, 2.2)
0.0 (− 0.9, 0.9)
0.91
 Adjusted difference (95% CI)b
Reference
− 0.3 (3.6, 3.0)
− 0.8 (− 4.1, 2.5)
1.0 (− 2.6, 4.6)
0.9 (− 4.3, 2.5)
0.0 (− 0.9, 1.1)
0.90
 Adjusted difference (95% CI)c
Reference
− 1.3 (− 4.1, 1.4)
− 1.7 (− 4.3, 1.0)
− 0.5 (− 3.4, 2.4)
− 0.7 (− 3.3, 1.9)
− 0.1 (− 0.8, 0.6)
0.90
RBP4 (μg/mL)
 Mean ± SD
4.2 ± 0.9
4.2 ± 0.7
3.9 ± 0.5
4.0 ± 0.6
3.8 ± 0.5
   
 Unadjusted difference (95% CI)a
Reference
0.0 (− 0.3, 0.2)
− 0.3 (− 0.6, − 0.1)
− 0.2 (− 0.5, − 0.1)
− 0.4 (− 0.7, − 0.2)
− 0.1 (− 0.2, − 0.1)
 < 0.001*
 Adjusted difference (95% CI)b
Reference
0.0 (− 0.3, 0.3)
− 0.3 (− 0.6, 0.0)
− 0.2 (− 0.5, 0.0)
− 0.4 (− 0.7, − 0.2)
− 0.1 (− 0.2, − 0.05)
0.001*
 Adjusted difference (95% CI)c
Reference
0.0 (− 0.3, 0.2)
− 0.3 (− 0.6, − 0.1)
− 0.2 (− 0.5, 0.0)
− 0.4 (− 0.7, − 0.2)
− 0.1 (− 0.2, − 0.05)
0.001*
Chemerin (ng/mL)
 Mean ± SD
75.0 ± 65.4
74.6 ± 58.2
89.7 ± 68.9
89.3 ± 71.1
89.2 ± 58.9
   
 Unadjusted difference (95% CI)a
Reference
− 0.4 (− 20.3, 19.4)
14.6 (− 6.8, 36.1)
14.3 (− 7.5, 36.1)
14.2 (− 5.7, 34.2)
6.1 (− 0.5, 12.7)
0.07
 Adjusted difference (95% CI)b
Reference
1.1 (− 19.1, 21.2)
18.4 (− 3.1, 39.9)
17.3 (− 5.2, 39.7)
16.6 (− 4.6, 37.8)
7.4 (0.4, 14.4)
0.04*
 Adjusted difference (95% CI)c
Reference
− 0.1 (− 20.4, 20.2)
17.3 (− 4.1, 38.8)
16.3 (− 6.5, 38.1)
17.6 (− 4.2, 37.8)
7.2 (0.3, 14.1)
0.04*
95% CI 95% confidence interval, Q quintiles, SD standard deviation
P < 0.05*
aFrom linear regression models with each adipokine as a continuous outcome and C-DII as predictor. Robust estimates of variance were specified in all models
bFrom linear regression adjusted for child’s age, sex, race, per capita income and screen time
cFrom linear regression adjusted for child’s age, sex, race, per capita income, screen time and % body fat
dFor a variable representing ordinal C-DII categories introduced as a continuous predictor
Metadata
Title
Correction to: The dietary inflammatory index is associated with anti and pro‑inflammatory adipokines in Brazilian schoolchildren
Authors
Lara Gomes Suhett
H. H. M. Hermsdorff
Sarah Aparecida Vieira Ribeiro
Mariana De Santis Filgueiras
Nitin Shivappa
James R. Hébert
Juliana Farias de Novaes
Publication date
01-08-2021
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nutrition / Issue 5/2021
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-021-02544-w

Other articles of this Issue 5/2021

European Journal of Nutrition 5/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine